RCS - Angle PLC - Parsortix unlocks opportunities for drug discovery

AngleAnnouncement

11/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231211:nRSK2326Wa&default-theme=true

RNS Number : 2326W  Angle PLC  11 December 2023

 For immediate release  11 December 2023

 

ANGLE plc ("the Company")

 

USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG
DISCOVERY

 

Harvested CTCs reveal gene expression profile associated with development and
progression of brain metastasis in melanoma

 

Researchers suggest such profiling could prove to be "pivotal" to prescribing
more targeted treatments in this setting

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, is delighted to announce the
publication of breakthrough work by researchers at the University of New
Mexico, US, into the role of CTC gene expression in the progression of
melanoma brain metastasis. The researchers used the Parsortix system to
harvest CTCs for analysis and concluded that "… gene expression in CTCs
could be pivotal to prescribing more targeted treatment based on the needs of
the patient."

 

In this study, pre-clinical mouse models of melanoma brain metastasis were
split into four treatment groups and two cancer drugs were tested individually
and together vs. placebo. Blood samples were analysed using the Parsortix
system to harvest CTCs. The authors found that using the two drugs together
was the most effective therapeutic regime, reducing tumour burden, metastasis
and CTC count.

 

This research provides further evidence of the capability of the Parsortix
system to be used for the harvesting of CTCs for analysis in pre-clinical
mouse models.

 

The global market for preclinical clinical research organisations exceeded a
valuation of US$ 5 billion in 2022 and is expected to achieve a 7.5% CAGR over
the next 10 years owing to increasing R&D expenditure on early-stage
development combined with the growing number of drugs in preclinical
development.

 

 

ANGLE Chief Executive Officer, Andrew Newland, commented:

"The use of CTC biomarkers in clinical trials is a rapidly growing field
enabling longitudinal monitoring of transcriptomic and proteomic changes.
ANGLE can provide pharma customers with a complete range of services to
support preclinical and clinical drug development. This includes standardised
and validated protocols for analysing CTCs including the established
techniques of IF, dPCR and NGS, and the capability to deliver bespoke assays
to identify drug targets and ascertain therapeutic efficacy."

 

This peer-reviewed journal article is published in the journal of Cancers and
available at www.angleplc.com/publications
(http://www.angleplc.com/publications) .

 

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK and the United States.  Services include
custom made assay development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEASAPESNDFFA